Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
Celltrion announces phase 3 trial data for EYDENZELT
(Image credit: ©HockleyM2) Celltrion recently announced 52-week findings from its global phase 3 clinical trial for its ophthalmic treatment candidate, EYDENZELT.1 EYDENZELT, a biosimilar of EYLEA (aflibercept), is Celltrion’s ophthalmic treatment candidate for the treatment of multiple retinal diseases, including…
Alcon completes acquisition of LumiThera
(Image Credit: AdobeStock/Timon) Alcon has completed its planned acquisition of LumiThera, Inc, which was announced earlier in July of this year.1,2 According to Alcon, the acquisition includes the noninvasive Valeda photobiomodulation (PBM) device for the treatment of early and intermediate dry…
Ashvattha reports positive phase 2 results for migaldendranib in DME and nAMD
(Image Credit: AdobeStock) Ashvattha Therapeutics shared positive topline data from its phase 2 study of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The topline end-of-study results were announced at the 25th…
Sight Science’s TearCare System earns spot in TFOS DEWS III dry eye report
(Image Credit: AdobeStock/tadamichi) Sight Sciences announced that its TearCare System has been included in the new Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS) published in the American Journal of Ophthalmology.1,2 This marks the…
Outlook Therapeutics requests Type A meeting with FDA following second CRL for ONS-5010
(Image Credit: AdobeStock) Outlook Therapeutics has requested a Type A meeting with the US Food and Drug Administration following the agency issuing a complete response letter (CRL) to its biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment…
The state of retina at ASRS 2025 with Charles C. Wykoff, MD, PhD, and Kevin Quinn
(Image credit: AdobeStock/vetrana) The annual scientific meeting of the American Society of Retina Specialists (ASRS) was held in Long Beach, California from July 30 through August 2, 2025. At this event, researchers and experts in the retina field shared data…
EMA grants Orphan designations to MCO-010, FDA grants RMAT in Stargardt disease
(Image credit: AdobeStock/Pete) The European Medicines Agency (EMA) granted Orphan designations to MCO-010 (sonpiretigene isteparvovec) across 5 categories of retinal dystrophies. The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD). The EMA…
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences – The Manila Times
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences The Manila Times Source: Author: | Date: 2025-09-01 08:15:00 Source: Author: | Date: 2025-09-01 08:15:00
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences – Yahoo Finance
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences Yahoo Finance Source: Author: | Date: 2025-09-01 08:00:00 Source: Author: | Date: 2025-09-01 08:00:00